Saliva α-synuclein and a high extinction coeffi cient protein: A novel approach in assessment biomarkers of parkinson’s disease

North American Journal of Medical Sciences

Volumn 6, Issue 12, 2014, Pages 633-637

  Al Nimer, Marwan S M ^a   Mshatat, Sabah F ^a   Abdulla, Hajer I ^a  

^a MUSTANSIRIYAH UNIVERSITY   (Iraq)

Author keywords

Parkinson s disease; Saliva; synuclein

Indexed keywords

ALPHA SYNUCLEIN; SALIVA PROTEIN;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERSALIVATION; MALE; OBSERVATIONAL STUDY; PARKINSON DISEASE; RIGIDITY; TOOTH FILLING; TREMOR; ULTRAVIOLET SPECTROPHOTOMETRY; UNIFIED PARKINSON DISEASE RATING SCALE; XEROSTOMIA;

EID: 84920026565     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.147980     Document Type: Article

References (22)

1. Louis ED, Bennett DA. Mild parkinsonian signs: An overview of an emerging concept. Mov Disord 2007;22:1681-8.
2. Beach TG, Adler CH, Lue LF, Sue LI, Bachalakuir J, Henry-Watson J, et al. Arizona Parkinson’s Disease Consortium. Unifi ed staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613-34.
3. Gründemann J, Schlaudraff F, Haeckel O, Liss B. Elevated α-synuclein mRNA levels in individual UV-lasermicrodissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res 2008;36:e38.
4. Maiti NC, Apetri MM, Zagorski MG, Carey PR, Anderson VE. Raman spectroscopic characterization of secondary structure in natively unfolded proteins: Alpha-synuclein. J Am Chem Soc 2004;126:2399-408.
5. Bonini NM, Giasson BI. Snaring the function of alphasynuclein. Cell 2005;123:359-61.
6. Wu KP, Kim S, Fela DA, Baum J. Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: Implication for aggregation. J Mol Biol 2008;378:1104-15.
7. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and α-synuclein in human cerebrospinal fl uid as biomarkers of Parkinson’s disease. Brain 2010;133:713-26.
8. Cersósimo MG, Tumilasci OR, Raina GB, Benarroch EE, Cardoso EM, Micheli F, et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci 2009;150:150-1.
9. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary α-synuclein and DJ-1: Potential biomarkers for Parkinson›s disease. Brain 2011;134:e178.
10. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al., Arizona Parkinson’s Disease Consortium. Multiorgan distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
11. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010;119:703-13.
12. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al., Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unifi ed Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-70.
13. Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
14. Stoscheck CM. Quantitation of protein. Methods Enzymol 1990;182:50-68.
15. Clarimón J, Kulisevsky J. Parkinson’s disease: From genetics to clinical practice. Curr Genomics 2013;14:560-7.
16. Chang RC, Ho YS, Wong S, Gentleman SM, Ng HK. Neuropathology of cigarette smoking. Acta Neuropathol 2014;127:53-69.
17. Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs 2013;18:39-53.
18. Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson’s disease: Prevalence and occurrence before motor symptoms. J Neurol 2013;260:1332-8.
19. Rana AQ, Khondker S, Kabir A, Owalia A, Khondker S, Emre M. Impact of cognitive dysfunction on drooling in Parkinson’s disease. Eur Neurol 2013;70:42-5.
20. Cicciù M, Matacena G, Signorino F, Brugaletta A, Cicciù A, Bramanti E. Relationship between oral health and its impact on the quality life of Alzheimer’s disease patients: A supportive care trial. Int J Clin Exp Med 2013;6:766-72.
21. Pradeep AR, Singh SP, Martande SS, Raju AP, Rustagi T, Suke DK, et al. Clinical evaluation of the periodontal health condition and oral health awareness in Parkinson’s disease patients. Gerodontology 2013.
22. Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 2011;108:17797-802.